This manuscript describes the development of the first of its kind CD99-A192/FLT3-A192 nanoparticles that bind to both CD99 and FLT3 and reports the therapeutic effects of this novel dual-targeting approach in AML preclinical models. This evidence concerns the gene FLT3 and acute myeloid leukemia.